Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H35NO5 |
Molecular Weight | 429.5501 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CCCCOC(=O)c1ccc(c(c1)OC)OC)C(C)Cc2ccc(cc2)OC
InChI
InChIKey=VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
DescriptionCurator's Comment:: description was created based on several sources, including:
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Curator's Comment:: description was created based on several sources, including:
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Alpha-1 adrenergic receptor (guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2442008 |
|||
Target ID: Muscarinic acetylcholine receptors (guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2442008 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Colofac Approved UseColofac is used to treat symptoms of irritable bowel syndrome and similar problems. Launch Date2.58595193E11 |
|||
Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Launch Date2.58595193E11 |
|||
Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis Launch Date2.58595193E11 |
PubMed
Title | Date | PubMed |
---|---|---|
The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS. | 2001 Jul-Aug |
|
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. | 2001 Mar |
|
A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. | 2002 Nov |
|
On-line micellar electrokinetic chromatography-mass spectrometry: feasibility of direct introduction of non-volatile buffer and surfactant into the electrospray interface. | 2003 Jun 6 |
|
Spectrophotometric microdetermination of nefopam, mebevrine and phenylpropanolamine hydrochloride in pharmaceutical formulations using alizarins. | 2004 Jul |
|
[Abdominal migraine as a cause of chronic recurrent abdominal pain in a 9-years-old girl--case report]. | 2005 Aug |
|
Simultaneous determination of mebeverine hydrochloride and sulpiride using the first derivatives of ratio spectra and chemometric methods. | 2005 Aug |
|
Atmospheric pressure photoionization for enhanced compatibility in on-line micellar electrokinetic chromatography-mass spectrometry. | 2005 Aug 15 |
|
Potentiometric flow injection analysis of mebeverine hydrochloride in serum and urine. | 2005 Jan 4 |
|
[Mebeverine for complex treatment of opisthorchiasis]. | 2006 |
|
A validated chiral HPLC method for the determination of mebeverine HCl enantiomers in pharmaceutical dosage forms and spiked rat plasma. | 2006 Feb |
|
"My patients are the sickest". | 2006 May |
|
[Assessment of the efficacy of mebeverine in the complex therapy of chronic noncalculolis cholecystitis and biliary dysfunction]. | 2007 |
|
Development of in situ ion selective sensors for dissolution. | 2007 Jan 2 |
|
[Drug treatment of irritable bowel syndrome: an unmet need]. | 2007 Mar |
|
[Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome]. | 2008 |
|
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. | 2008 Nov 13 |
|
Drug use in children: cohort study in three European countries. | 2008 Nov 24 |
|
[The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis]. | 2009 |
|
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality. | 2009 |
|
pH-Sensitive Mebeverine Microspheres for Colon Delivery. | 2009 Jul |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
First derivative synchronous fluorescence spectroscopy for the simultaneous determination of sulpiride and mebeverine hydrochloride in their combined tablets and application to real human plasma. | 2010 Nov |
|
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). | 2010 Nov 18 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicines.org.uk/emc/PIL.22522.latest.pdf
One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2444442
Mebeverine (10^5-10^4 M) suppressed the amplitude of the action potential and lengthened the time between stimulation and the top of the response in non-myelinated fibres of the vagus nerve.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
||
|
WHO-ATC |
A03AA04
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
||
|
WHO-VATC |
QA03AA04
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3625-06-7
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
7F80CC3NNV
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
1642
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
3625-06-7
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
29410
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | RxNorm | ||
|
4031
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
222-830-4
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
CHEMBL282121
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
SUB08662MIG
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
M7108
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | Merck Index | ||
|
C005096
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
MEBEVERINE
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
1191
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
DB12554
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
C83909
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)